Marina C. Garassino, MD | Authors

Articles

Interpreting the Role of the Ramucirumab Plus Erlotinib Combination in EGFR+ NSCLC

June 18, 2019

Marina C. Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy, discusses the results from the randomized phase III RELAY trial, in which the combination of ramucirumab plus erlotinib was compared to erlotinib plus placebo in patients with EGFR-mutated non–small cell lung cancer. These data were presented at the 2019 ASCO Annual Meeting.